LGND has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
LGND has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.
Ligand Pharmaceuticals's adjusted earnings per share data for the three months ended in Mar. 2024 was $4.750. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $6.64 for the trailing ten years ended in Mar. 2024.
During the past 12 months, Ligand Pharmaceuticals's average E10 Growth Rate was 9.20% per year. During the past 3 years, the average E10 Growth Rate was 7.50% per year. During the past 5 years, the average E10 Growth Rate was 21.20% per year. During the past 10 years, the average E10 Growth Rate was 34.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.
During the past 13 years, the highest 3-Year average E10 Growth Rate of Ligand Pharmaceuticals was 141.00% per year. The lowest was -9.30% per year. And the median was 25.20% per year.
As of today (2024-05-13), Ligand Pharmaceuticals's current stock price is $87.28. Ligand Pharmaceuticals's E10 for the quarter that ended in Mar. 2024 was $6.64. Ligand Pharmaceuticals's Shiller PE Ratio of today is 13.14.
During the past 13 years, the highest Shiller PE Ratio of Ligand Pharmaceuticals was 266.47. The lowest was 8.13. And the median was 18.08.
The historical data trend for Ligand Pharmaceuticals's E10 can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ligand Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
E10 | Get a 7-Day Free Trial | 6.08 | 6.12 | 6.10 | 6.17 | 6.64 |
For the Biotechnology subindustry, Ligand Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Ligand Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:
* The bar in red indicates where Ligand Pharmaceuticals's Shiller PE Ratio falls into.
E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.
What is E10? How do we calculate E10?
E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.
If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.
We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
For example, Ligand Pharmaceuticals's adjusted earnings per share data for the three months ended in Mar. 2024 was:
Adj_EPS | = | Earnings per Share (Diluted) | / | CPI of Mar. 2024 (Change) | * | Current CPI (Mar. 2024) |
= | 4.75 | / | 129.4194 | * | 129.4194 | |
= | 4.750 |
Current CPI (Mar. 2024) = 129.4194.
Ligand Pharmaceuticals Quarterly Data
per share eps | CPI | Adj_EPS | |
201406 | 0.070 | 100.560 | 0.090 |
201409 | 0.060 | 100.428 | 0.077 |
201412 | 0.340 | 99.070 | 0.444 |
201503 | 0.040 | 99.621 | 0.052 |
201506 | 1.110 | 100.684 | 1.427 |
201509 | 9.280 | 100.392 | 11.963 |
201512 | 0.290 | 99.792 | 0.376 |
201603 | 0.300 | 100.470 | 0.386 |
201606 | -0.300 | 101.688 | -0.382 |
201609 | 0.050 | 101.861 | 0.064 |
201612 | -0.150 | 101.863 | -0.191 |
201703 | 0.220 | 102.862 | 0.277 |
201706 | 0.260 | 103.349 | 0.326 |
201709 | 0.360 | 104.136 | 0.447 |
201712 | -0.330 | 104.011 | -0.411 |
201803 | 1.830 | 105.290 | 2.249 |
201806 | 2.990 | 106.317 | 3.640 |
201809 | 2.800 | 106.507 | 3.402 |
201812 | -2.020 | 105.998 | -2.466 |
201903 | 31.320 | 107.251 | 37.794 |
201906 | -0.740 | 108.070 | -0.886 |
201909 | -0.810 | 108.329 | -0.968 |
201912 | -0.430 | 108.420 | -0.513 |
202003 | -1.460 | 108.902 | -1.735 |
202006 | 1.320 | 108.767 | 1.571 |
202009 | -0.420 | 109.815 | -0.495 |
202012 | 0.350 | 109.897 | 0.412 |
202103 | 1.050 | 111.754 | 1.216 |
202106 | 1.790 | 114.631 | 2.021 |
202109 | 0.800 | 115.734 | 0.895 |
202112 | -0.300 | 117.630 | -0.330 |
202203 | -0.910 | 121.301 | -0.971 |
202206 | -0.050 | 125.017 | -0.052 |
202209 | 0.020 | 125.227 | 0.021 |
202212 | -1.040 | 125.222 | -1.075 |
202303 | 2.330 | 127.348 | 2.368 |
202306 | 0.130 | 128.729 | 0.131 |
202309 | -0.590 | 129.860 | -0.588 |
202312 | 1.030 | 129.419 | 1.030 |
202403 | 4.750 | 129.419 | 4.750 |
Add all the adjusted EPS together and divide 10 will get our e10.
If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.
For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.
The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.
Ligand Pharmaceuticals's Shiller P/E Ratio of today is calculated as
Shiller PE Ratio | = | Share Price | / | E10 |
= | 87.28 | / | 6.64 | |
= | 13.14 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
During the past 13 years, the highest Shiller P/E Ratio of Ligand Pharmaceuticals was 266.47. The lowest was 8.13. And the median was 18.08.
Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.
Thank you for viewing the detailed overview of Ligand Pharmaceuticals's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.
Martine Zimmermann | director | C/O LIGAND PHARMACEUTICALS INCORPORATED, 3911 SORRENTO VALLEY BOULEVARD SUITE 110, SAN DIEGO CA 92121 |
Todd C Davis | director | 11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037 |
Andrew Reardon | officer: CHIEF LEGAL OFFICER & | C/O LIGAND PHARMACEUTICALS INCORPORATED, 3911 SORRENTO VALLEY BLVD, SUITE 110, SAN DIEGO CA 92121 |
Octavio Espinoza | officer: Chief Financial Officer | C/O LIGAND PHARMACEUTICALS INC, 3911 SORRENTO VALLEY BOULEVARD, STE 110, SAN DIEGO CA 92121 |
John W Kozarich | director | 10275 SCIENCE CENTER DR, SAN DIEGO CA 92121 |
Stephen L Sabba | director | DORSET MANAGEMENT CORP, 485 UNDERHILL BLVD SUITE 205, SYOSSET NY 11791 |
John L Higgins | officer: CEO & President | 11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037 |
Jason Haas | director | C/O SYROS PHARMACEUTICALS, INC., 35 CAMBRIDGEPARK DRIVE, CAMBRIDGE MA 02140 |
Matthew W Foehr | officer: EVP and COO | 11119 NORTH TORREY PINES RD #200, LA JOLLA CA 92037 |
John L Lamattina | director | 81 WYMAN ST, POST OFFICE BOX 9046, WALTHAM MA 02454 |
Jennifer R. Cochran | director | C/O LIGAND PHARMACEUTICALS INC, 3911 SORRENTO VALLEY BOULEVARD, STE 100, SAN DIEGO CA 92121 |
Charles S Berkman | officer: Asso. Gen. Counsel, Secretary | 11085 NORTH TORREY PINES ROAD, SUITE 300, LA JOLLA CA 92037 |
Sunil Patel | director | 11085 NORTH TORREY PINES RD., SUITE 300, LA JOLLA CA 92037 |
Goldman Sachs Group Inc | 10 percent owner | 200 WEST STREET, NEW YORK NY 10282 |
Goldman Sachs & Co. Llc | 10 percent owner | 200 WEST STREET, NEW YORK NY 10282 |
From GuruFocus
By Business Wire • 09-26-2023
By Marketwired • 11-06-2023
By Business Wire • 09-22-2023
By Business Wire • 07-25-2023
By Business Wire Business Wire • 04-24-2023
By Business Wire • 10-25-2023
By Business Wire • 07-17-2023
By Business Wire • 01-05-2024